James Cain, MD
Nephrology · Sumter, SCNPI 1174615868
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Amgen at 26.0% of the total. Reporting peaked in 2023 at $1,230 and has fallen 92.6% since, to $91 in 2025.
Across 235 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$469
- Aurinia Pharma U.S., Inc.$338
- Novo Nordisk$310
- Vifor Pharma, Inc.$260
- Otsuka America Pharmaceutical, Inc.$237
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,70499%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 66 | $1,240 |
| AstraZeneca(2 entities) | 25 | $469 |
| Aurinia Pharma U.S., Inc. | 13 | $338 |
| Novo Nordisk | 15 | $310 |
| Vifor Pharma, Inc. | 14 | $260 |
| Otsuka America Pharmaceutical, Inc. | 10 | $237 |
| Mallinckrodt Hospital Products Inc. | 8 | $216 |
| Calliditas Therapeutics US Inc. | 8 | $174 |
| Alnylam Pharmaceuticals Inc. | 8 | $173 |
| GSK | 8 | $153 |
| Corcept Therapeutics | 3 | $118 |
| Bayer | 6 | $112 |
| Novartis | 6 | $106 |
| OPKO Pharmaceuticals, LLC | 6 | $92 |
| Madrigal Pharmaceuticals | 1 | $91 |
| Merck | 6 | $81 |
| Abbott | 4 | $66 |
| Boehringer Ingelheim | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Renalytix AI, Inc. | 3 | $55 |
| Lilly USA, LLC | 3 | $50 |
| Pfizer | 2 | $38 |
| Ardelyx, Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| AbbVie | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| G Medical Diagnostic Services, Inc. | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
How this compares
$4,764 in reported general payments places this provider in the 75th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 169 | $143,834 |
| OzempicSemaglutide | 83 | $100,214 |
| JardianceEmpagliflozin | 59 | $59,366 |
| TrulicityDulaglutide | 37 | $37,414 |
| VelphoroSucroferric Oxyhydroxide | 16 | $36,254 |
| LokelmaSodium Zirconium Cyclosilicate | 43 | $35,887 |
| EliquisApixaban | 34 | $30,833 |
| EntrestoSacubitril/Valsartan | 12 | $23,270 |
| MounjaroTirzepatide | 17 | $19,925 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $16,931 |
| Sevelamer Carbonate | 46 | $12,311 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,638 |
| Calcium Acetate | 43 | $4,172 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,628 |
| Losartan Potassium | 158 | $2,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $469 | $179,721212 claims |
| Novo NordiskOzempic | $310 | $100,21483 claims |
| Boehringer IngelheimJardiance | $62 | $59,36659 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $50 | $57,33954 claims |
| PfizerEliquis | $38 | $30,83334 claims |
| NovartisEntresto | $106 | $23,27012 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $22 | $1,66647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Sumter
- Mohammed AlzubaidiSumter$54K
- Pusadee SuchindaSumter$12K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.